FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021017717> ?p ?o ?g. }

• W2021017717 endingPage "1191" @default.
• W2021017717 startingPage "1183" @default.
• W2021017717 abstract "1. The novel tri-aryl ethane CDP840, is a potent and selective inhibitor of cyclic AMP phosphodiesterase type 4 (PDE 4) extracted from tissues or recombinant PDE 4 isoforms expressed in yeast (IC50S: 4-45 nM). CDP840 is stereo-selective since its S enantiomer (CT 1731) is 10-50 times less active against all forms of PDE 4 tested while both enantiomers are inactive (IC50S: > 100 microM) against PDE types 1, 2, 3 and 5. 2. Oral administration of CDP840 caused a dose-dependent reduction of interleukin-5 (IL-5)-induced pleural eosinophilia in rats (ED50 = 0.03 mg kg-1). The eosinophils in pleural exudates from CDP840-treated animals contained higher levels of eosinophil peroxidase (EPO) than cells from control animals, suggesting a stabilizing effect on eosinophil degranulation. CDP840 was approximately equi-active with the steroid dexamethasone in this model and was 10-100 times more potent than the known PDE 4-selective inhibitors rolipram and RP73401. The activity of CDP840 was not influenced by adrenalectomy, beta-sympathomimetics or beta-sympatholytics. 3. Antigen-induced pulmonary eosinophilia in sensitized guinea-pigs was reduced dose-dependently by CDP840 (0.01-1 mg kg-1, i.p.) and intracellular EPO levels were significantly higher. CDP840 was more potent in these activities than CT1731 or rolipram and comparable in potency to RP73401. 4. Rolipram or CDP840 were less active than dexamethasone in preventing neutrophil accumulation, or exudate formation in carrageenan-induced pleurisy in rats and thus do not exhibit general anti-inflammatory activity. 5. In sensitized guinea-pigs, aerosols of the antigen ovalbumin caused a dose-dependent bronchoconstriction demonstrated by an increase in pulmonary inflation pressure. Administration of CDP840 (0.001-1.0 mg kg-1, i.p.), 1 h before antigen challenge, resulted in dose-dependent reduction in response to antigen. This activity was not due to bronchodilatation since higher doses of CDP840 (3 mg kg-1) did not significantly change the bronchoconstrictor response to histamine. Rolipram was approximately 10 times less active than CDP840 in preventing antigen-induced bronchoconstriction. 6. These results confirm the observations that selective PDE 4 inhibitors reduce antigen-induced bronchoconstriction and pulmonary eosinophilic inflammation. CDP840 is more potent than rolipram in inhibiting native or recombinant PDE 4. Unlike the recently described potent PDE 4 inhibitor RP73401, CDP840 is more active than rolipram in the rat IL-5 model following oral administration. The novel series of tri-aryl ethanes, of which CDP840 is the lead compound, could be the basis of an orally active prophylactic treatment for human asthma." @default.
• W2021017717 created "2016-06-24" @default.
• W2021017717 creator A5000745470 @default.
• W2021017717 creator A5004053279 @default.
• W2021017717 creator A5006045347 @default.
• W2021017717 creator A5006159717 @default.
• W2021017717 creator A5009786117 @default.
• W2021017717 creator A5020497751 @default.
• W2021017717 creator A5027787851 @default.
• W2021017717 creator A5030383736 @default.
• W2021017717 creator A5030951176 @default.
• W2021017717 creator A5032170452 @default.
• W2021017717 creator A5034968216 @default.
• W2021017717 creator A5036598848 @default.
• W2021017717 creator A5049745612 @default.
• W2021017717 creator A5050703897 @default.
• W2021017717 creator A5053717275 @default.
• W2021017717 creator A5058577365 @default.
• W2021017717 creator A5059425657 @default.
• W2021017717 creator A5061836425 @default.
• W2021017717 creator A5063573200 @default.
• W2021017717 creator A5065386073 @default.
• W2021017717 creator A5080391581 @default.
• W2021017717 creator A5082062728 @default.
• W2021017717 creator A5084436879 @default.
• W2021017717 creator A5086565125 @default.
• W2021017717 creator A5091007598 @default.
• W2021017717 date "1996-07-01" @default.
• W2021017717 modified "2023-09-27" @default.
• W2021017717 title "The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4" @default.
• W2021017717 cites W1498706619 @default.
• W2021017717 cites W1516350423 @default.
• W2021017717 cites W1548820511 @default.
• W2021017717 cites W1732449795 @default.
• W2021017717 cites W1800918825 @default.
• W2021017717 cites W1895515385 @default.
• W2021017717 cites W1909984090 @default.
• W2021017717 cites W1966337309 @default.
• W2021017717 cites W1977177612 @default.
• W2021017717 cites W1983963555 @default.
• W2021017717 cites W1986047818 @default.
• W2021017717 cites W2000312049 @default.
• W2021017717 cites W2006512568 @default.
• W2021017717 cites W2037663265 @default.
• W2021017717 cites W2040836708 @default.
• W2021017717 cites W2042252812 @default.
• W2021017717 cites W2045927761 @default.
• W2021017717 cites W2050367027 @default.
• W2021017717 cites W2050901258 @default.
• W2021017717 cites W2059783629 @default.
• W2021017717 cites W2062616704 @default.
• W2021017717 cites W2071331983 @default.
• W2021017717 cites W2071423801 @default.
• W2021017717 cites W2080119725 @default.
• W2021017717 cites W2090214382 @default.
• W2021017717 cites W2101353664 @default.
• W2021017717 cites W2124603568 @default.
• W2021017717 cites W2164508592 @default.
• W2021017717 cites W2263619267 @default.
• W2021017717 cites W2471034507 @default.
• W2021017717 cites W4254104742 @default.
• W2021017717 cites W2050030598 @default.
• W2021017717 doi "https://doi.org/10.1111/j.1476-5381.1996.tb15522.x" @default.
• W2021017717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1909599" @default.
• W2021017717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8818342" @default.
• W2021017717 hasPublicationYear "1996" @default.
• W2021017717 type Work @default.
• W2021017717 sameAs 2021017717 @default.
• W2021017717 citedByCount "95" @default.
• W2021017717 countsByYear W20210177172013 @default.
• W2021017717 countsByYear W20210177172015 @default.
• W2021017717 countsByYear W20210177172016 @default.
• W2021017717 countsByYear W20210177172017 @default.
• W2021017717 countsByYear W20210177172019 @default.
• W2021017717 countsByYear W20210177172020 @default.
• W2021017717 crossrefType "journal-article" @default.
• W2021017717 hasAuthorship W2021017717A5000745470 @default.
• W2021017717 hasAuthorship W2021017717A5004053279 @default.
• W2021017717 hasAuthorship W2021017717A5006045347 @default.
• W2021017717 hasAuthorship W2021017717A5006159717 @default.
• W2021017717 hasAuthorship W2021017717A5009786117 @default.
• W2021017717 hasAuthorship W2021017717A5020497751 @default.
• W2021017717 hasAuthorship W2021017717A5027787851 @default.
• W2021017717 hasAuthorship W2021017717A5030383736 @default.
• W2021017717 hasAuthorship W2021017717A5030951176 @default.
• W2021017717 hasAuthorship W2021017717A5032170452 @default.
• W2021017717 hasAuthorship W2021017717A5034968216 @default.
• W2021017717 hasAuthorship W2021017717A5036598848 @default.
• W2021017717 hasAuthorship W2021017717A5049745612 @default.
• W2021017717 hasAuthorship W2021017717A5050703897 @default.
• W2021017717 hasAuthorship W2021017717A5053717275 @default.
• W2021017717 hasAuthorship W2021017717A5058577365 @default.
• W2021017717 hasAuthorship W2021017717A5059425657 @default.
• W2021017717 hasAuthorship W2021017717A5061836425 @default.
• W2021017717 hasAuthorship W2021017717A5063573200 @default.
• W2021017717 hasAuthorship W2021017717A5065386073 @default.
• W2021017717 hasAuthorship W2021017717A5080391581 @default.
• W2021017717 hasAuthorship W2021017717A5082062728 @default.

• next